挽救性放疗对晚期局部复发鼻咽癌患者生存的影响:预测模型的推导与验证
本研究纳入809例在高容量癌症中心诊断为晚期局部复发鼻咽癌并接受挽救性放疗或姑息性化疗的患者,随机分为训练集和验证集并用逆概率处理加权匹配。基于Cox模型交互项构建的挽救性放疗结局评分(SARTOS)可显著预测挽救性放疗的治疗效应,高SARTOS亚组中挽救性放疗较姑息性化疗显著改善生存,低SARTOS亚组中挽救性放疗未能带来生存获益。
要点
- SARTOS模型可识别从挽救性放疗较姑息性化疗中获益的晚期局部复发鼻咽癌患者亚组。
- 高SARTOS亚组中挽救性放疗较姑息性化疗显著改善生存,训练集3年OS 67.3% vs 42.0%,验证集71.8% vs 22.8%。
- 低SARTOS亚组中挽救性放疗未能诱导生存获益。
核心结论
- SARTOS模型可识别从挽救性放疗较姑息性化疗中获益的患者亚组,有助于为复发鼻咽癌患者个体化制定治疗推荐。
研究设计与样本
- 共纳入809例在高容量癌症中心诊断为晚期局部复发鼻咽癌并接受挽救性放疗或姑息性化疗的患者。
- 患者被随机分为训练集和验证集,并使用逆概率处理加权进行匹配。
- 主要结局为总生存期(OS)。
- 通过与Cox模型中的交互项识别与异质性治疗效应相关的候选变量,并纳入挽救性放疗结局评分(SARTOS)。
主要发现
- 最终模型包含五个交互项,表明女性、既往放疗诱导的≥3级晚期毒性以及体能状态欠佳与挽救性放疗获益较少相关。
- SARTOS显著预测挽救性放疗的治疗效应,匹配训练队列交互作用P<0.001,验证队列交互作用P=0.027。
- 高SARTOS亚组中,挽救性放疗较姑息性化疗显著改善生存:匹配训练队列3年OS 67.3% vs 42.0%(HR 0.51,95% CI 0.32-0.82,P=0.005),验证队列3年OS 71.8% vs 22.8%(HR 0.40,95% CI 0.17-0.97,P=0.042)。
- 低SARTOS亚组中,挽救性放疗未能诱导生存获益。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Salvage radiotherapy (RT) is a potentially curative approach for advanced locally recurrent nasopharyngeal carcinoma (NPC), but it is associated with severe toxicities. We aimed to develop a model to predict which patients would benefit from salvage RT. METHODS: A total of 809 patients who were diagnosed with advanced locally recurrent NPC and treated with salvage RT or palliative chemotherapy (CT) at a high-volume cancer center were included. Patients were randomly split into a training and validation set and matched using inverse probability of treatment weighting. The primary outcome was overall survival (OS). Candidate variables associated with heterogeneous treatment effects were identified with interaction terms in Cox model and incorporated into Salvage Radiotherapy Outcome Score (SARTOS). RESULTS: The final model included five interaction terms indicating that female sex, presence of prior RT-induced grade ≥ 3 late toxicities and suboptimal performance status were associated with less benefit from salvage RT. SARTOS from the model significantly predicted treatment effects of salvage RT in matched training (Pinteration < 0.001) and validation cohorts (Pinteration = 0.027). Of patients in high SARTOS subgroup, salvage RT significantly improved survival versus palliative CT in matched training (3-year OS 67.3% vs. 42.0%, HR 0.51, 95% CI 0.32-0.82, P = 0.005) and validation cohorts (3-year OS 71.8% vs. 22.8%, HR 0.40, 95% CI 0.17-0.97, P = 0.042); in low SARTOS subgroup, salvage RT failed to induce survival benefit. CONCLUSIONS: We found that the SARTOS model could identify a subgroup of patients who benefit from salvage RT versus palliative CT, which helps personalize treatment recommendations for patients with recurrent NPC.
引用
- Liu T, Shen BW, Liu LT, et al. Impact of salvage radiotherapy on survival of patients with advanced locally recurrent nasopharyngeal carcinoma: Derivation and validation of a predictive model. Radiother Oncol. 2022. PMID: 34998900. doi:10.1016/j.radonc.2021.12.046
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。